11 Apr 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Germany-based Medigene and SynCore Biotechnology, a member of Taiwan's Sinphar Pharmaceutical Group, expanded their existing exclusive licensing and supply contract into new regions for the supply and marketing of the Veregen ointment.
The medicine contains a catechin concentrate based on a defined extract obtained from green tea leaves for the treatment of genital warts.
SynCore will now be responsible for the approval process and commercialization of the drug for the throughout Asia (excluding China and Korea), in Australia and New Zealand. In addition to income from the production and supply of the ointment and the active ingredient, Medigene will receive payment when specific milestones are reached.
Medigene already has partnerships in Asia with GC Rise Pharmaceuticals for the distribution of Veregen in China with Kolon Pharmaceuticals for distribution in South Korea.
SynCore Biotechnology, which is a joint venture between Taiwanese listed drug company Sinphar Pharma and the National Health Research Institute, Taiwan, focuses on the development and pipeline management of new drugs.